An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy

Derrick S Fung, Jess T WhitsonDepartment of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX, USAAbstract: Glaucoma is a progressive, neurodegenerative optic nerve disease that can cause significant visual morbidity and affects over 60 million people worldwide. The only kn...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fung DS, Whitson JT
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/c0dd7ba5f4ad43eaae716b06f10dd0d7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c0dd7ba5f4ad43eaae716b06f10dd0d7
record_format	dspace
spelling	oai:doaj.org-article:c0dd7ba5f4ad43eaae716b06f10dd0d72021-12-02T00:23:06ZAn evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy1177-5483https://doaj.org/article/c0dd7ba5f4ad43eaae716b06f10dd0d72014-03-01T00:00:00Zhttp://www.dovepress.com/an-evidence-based-review-of-unoprostone-isopropyl-ophthalmic-solution--a16083https://doaj.org/toc/1177-5483 Derrick S Fung, Jess T WhitsonDepartment of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX, USAAbstract: Glaucoma is a progressive, neurodegenerative optic nerve disease that can cause significant visual morbidity and affects over 60 million people worldwide. The only known modifiable risk factor for glaucoma at this time is elevated intraocular pressure (IOP), which may be treated with medications, laser therapy, and/or incisional surgery. Topical ocular medications are commonly used as first-line therapy for glaucoma, although side effects may limit their use. Unoprostone is a novel 22-carbon ocular hypotensive agent that may be advantageous in treating some patients with open angle glaucoma or ocular hypertension. Unlike the 20-carbon prostanoids, such as latanoprost, that lower IOP primarily through an increase in uveoscleral outflow, unoprostone may lower IOP through increased aqueous outflow via the conventional trabecular meshwork pathway. Although not as efficacious as other prostanoids, unoprostone is effective for IOP reduction both as monotherapy and adjunctive therapy with timolol. Unoprostone has decreased affinity for the prostaglandin F2α receptor, which may explain its well tolerated ocular and systemic side effect profile compared with other prostanoids.Keywords: unoprostone, Rescula®, prostaglandin, glaucoma, medicationFung DSWhitson JTDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2014, Iss default, Pp 543-554 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Fung DS Whitson JT An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy
description	Derrick S Fung, Jess T WhitsonDepartment of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX, USAAbstract: Glaucoma is a progressive, neurodegenerative optic nerve disease that can cause significant visual morbidity and affects over 60 million people worldwide. The only known modifiable risk factor for glaucoma at this time is elevated intraocular pressure (IOP), which may be treated with medications, laser therapy, and/or incisional surgery. Topical ocular medications are commonly used as first-line therapy for glaucoma, although side effects may limit their use. Unoprostone is a novel 22-carbon ocular hypotensive agent that may be advantageous in treating some patients with open angle glaucoma or ocular hypertension. Unlike the 20-carbon prostanoids, such as latanoprost, that lower IOP primarily through an increase in uveoscleral outflow, unoprostone may lower IOP through increased aqueous outflow via the conventional trabecular meshwork pathway. Although not as efficacious as other prostanoids, unoprostone is effective for IOP reduction both as monotherapy and adjunctive therapy with timolol. Unoprostone has decreased affinity for the prostaglandin F2α receptor, which may explain its well tolerated ocular and systemic side effect profile compared with other prostanoids.Keywords: unoprostone, Rescula®, prostaglandin, glaucoma, medication
format	article
author	Fung DS Whitson JT
author_facet	Fung DS Whitson JT
author_sort	Fung DS
title	An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy
title_short	An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy
title_full	An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy
title_fullStr	An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy
title_full_unstemmed	An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy
title_sort	evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/c0dd7ba5f4ad43eaae716b06f10dd0d7
work_keys_str_mv	AT fungds anevidencebasedreviewofunoprostoneisopropylophthalmicsolution015forglaucomaplaceintherapy AT whitsonjt anevidencebasedreviewofunoprostoneisopropylophthalmicsolution015forglaucomaplaceintherapy AT fungds evidencebasedreviewofunoprostoneisopropylophthalmicsolution015forglaucomaplaceintherapy AT whitsonjt evidencebasedreviewofunoprostoneisopropylophthalmicsolution015forglaucomaplaceintherapy
_version_	1718403763784384512

An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy

Ejemplares similares